摘要
目前非小细胞肺癌已是世界上发病率最高的癌症之一,且其发病率在逐年增加,这种现状促使人们不断寻求各种治疗手段以期延长患者的生存期,改善患者的生活质量。本综述旨在通过迄今为止有关临床数据,全面讨论贝伐珠单抗在治疗非小细胞肺癌中的应用进展,探讨该药物在临床使用中可能出现的问题、患者的更有效选择以及未来的发展方向。
At present, non-small cell lung cancer is one of the highest incidence of cancers in the world, and its incidence increased year by year, this situation prompted people to continue to seek a variety of treatment in order to extend the survival of patients and improve the quality of life of patients. This review aims to discuss the progress of bevacizumab in the treatment of non-small cell lung cancer, through the clinical data so far to explore the clinical use of the drug, the choice of patients and the future direction of development.
作者
徐萍
李红梅
Ping XU Hongmei LI(Department of Oncology, Affiliated Hospital of Qingdao University, Qingdao 266000, Chin)
出处
《中国肺癌杂志》
CAS
CSCD
北大核心
2017年第4期272-277,共6页
Chinese Journal of Lung Cancer
关键词
贝伐珠单抗
肺肿瘤
不良反应
Bevacizumab
Lung neoplasms
Adverse events
